Figure 3
From: Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86
SPP86 selectively inhibits RET- mediated proliferation in thyroid cancer cell lines. (A) TPC1 cells expressing RET/PTC1, 8505C cells expressing mutant BRAFV600E and C643 expressing mutant RASG13R were cultured in medium containing 0.1% FBS in the presence of increasing doses of sorafenib or SPP86 for 72 h. Viability was expressed as a percentage of the untreated control population. The data in each panel represent the mean of at least 3 experiments ± S. E.; *p <0.05 for 8505C cells at 1–10 μM and C643 cells at 10 μM SPP86 vs. control, **p <0.0001 for TPC1 cells at 0.1- 10 μM SPP86 vs. control. (B) TPC1, 8505C and C643 cells were exposed to increasing concentrations of sorafenib in media containing 0.1% FBS for 72 h. Viability was expressed as a percentage of the untreated control population. The data in each panel represent the mean of 3 experiments ± S. E. for C643 and 8505C cells and the mean of 2 experiments ± S. E. for TCP1 cells; *p <0.05 for 0.1- 1.0 μM for TCP1 cells, 1.0 μM for C643 cells.